Cellular Biomedicine Group, Inc. (CBMG) News
Filter CBMG News Items
CBMG News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CBMG News Highlights
- For CBMG, its 30 day story count is now at 1.
- list("500 - Internal server error")
Latest CBMG News From Around the Web
Below are the latest news stories about Cellular Biomedicine Group Inc that investors may wish to consider to help them evaluate CBMG as an investment opportunity.
Cellular Biomedicine Group, Inc. Stockholders Approve MergerCellular Biomedicine Group, Inc. (NASDAQ: CBMG) ("CBMG" or the "Company") announced that, at the Company's special meeting of stockholders held today, its stockholders approved the proposal to adopt the previously announced Agreement and Plan of Merger, dated as of August 11, 2020 (the "Merger Agreement"), by and among CBMG, CBMG Holdings ("Parent") and CBMG Merger Sub Inc., a wholly-owned subsidiary of Parent ("Merger Sub"). The Merger Agreement provides for the merger of Merger Sub with and into CBMG (the "Merger"), with CBMG surviving the Merger as a wholly-owned subsidiary of Parent. Upon the closing of the Merger, CBMG's stockholders will receive $19.75 per share in cash for each share of CBMG common stock they own. |
Leading Proxy Advisory Firms Glass Lewis and ISS Recommend Cellular Biomedicine Group Stockholders Vote FOR Proposed MergerROCKVILLE, Md. and SHANGHAI , Jan. 28, 2021 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (NASDAQ: CBMG ) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, announced today that leading proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services Inc. have both recommended that the Company's stockholders vote FOR the proposal to adopt the definitive merger agreement that provides for the acquisition of CBMG for $19.75 in cash per share of common stock in a going private transaction (the "merger proposal"). The Company will hold a special meeting of the stockholders on February 8, 2021 at 9:00 a.m. Eastern time , at 9605 Medical Center Drive, Sui... |
SHAREHOLDER ALERT: Halper Sadeh LLP Investigates UROV, WTRE, CBMG, NAV; Shareholders Are Encouraged to Contact the FirmNEW YORK, Jan. 25, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Urovant Sciences Ltd. (NASDAQ: UROV) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Sumitovant Biopharma Ltd. for $16.25 per share. If you are an Urovant shareholder, click here to learn more about your rights and options. Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click here to learn more about your rights and options. Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concern... |
Lifshitz Law Firm, P.C. Announces Investigation of CBMG, HMSY, UROV, and WDRNEW YORK, NY / ACCESSWIRE / January 18, 2021 / Lifshitz Law Firm, P.:Cellular Biomedicine Group, Inc. |
ALERT: Halper Sadeh LLP Reminds Investors of Its Ongoing Merger Investigations; Shareholders are Encouraged to Contact the Firm – CBMG, CGIX, UROVNEW YORK, Jan. 16, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click here to learn more about your rights and options. Cancer Genetics, Inc. (NASDAQ: CGIX) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with StemoniX, Inc. Under the merger agreement, Cancer Genetics will acquire all of the outstanding capital stock of StemoniX... |
STOCKHOLDER ALERT: Monteverde & Associates Continues to Investigate the Following MergerNEW YORK, NY / ACCESSWIRE / January 15, 2021 /Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating: * Nielsen Holdings plc (NYSE:NLSN) relating to its agreement to sell Nielsen's Global Connect business to Advent International Corporation for approximately $2. Click here for more information: https://monteverdelaw. |
SHAREHOLDER ALERT: WeissLaw LLP Reminds IPOE, VSPR, ACAM and CBMG Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
MERGER INVESTIGATION: Halper Sadeh LLP Investigates CBMG, ALSK, UROV, NAV; Shareholders Are Encouraged to Contact the FirmNEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to a consortium that includes members of Cellular Biomedicine management and several entities. If you are a Cellular Biomedicine shareholder, click here to learn more about your rights and options.Alaska Communications Systems Group, Inc. (NASDAQ: ALSK) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ATN International, Inc. for $3.40 per share in cash. If you are an Alaska Communications shareholde... |
SHAREHOLDER ALERT: WeissLaw LLP Reminds VSPR, CIT, ACAM, and CBMG Shareholders About Its Ongoing InvestigationsIf you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: |
Cerebral Palsy Market Global Key players- Allergen Plc, Cellular Biomedicine Group, Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline Plc, Abbott Laboratories, Acorda Therapeutics, Inc. to 2023Market Scenario Cerebral palsy (CP) is a group of lifelong neurological disorders that affect movement and coordination, caused by damage to or abnormalities inside the developing brain of the infant. CP can occur before, during or soon after birth. Additionally, cerebral |